The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Empagliflozin and linagliptin (Glyxambi®) has been accepted for restricted use in adults aged 18 years and older with type 2 diabetes mellitus:
- To improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Glyxambi do not provide adequate glycaemic control
- When already being treated with the free combination of empagliflozin and linagliptin
The restriction limits use in line with the previous SMC advice on empagliflozin and linagliptin.
Perampanel suspension (Fycompa®) has been accepted for restricted use for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy. The restriction limits use to second-line adjunctive treatment in patients with refractory partial onset epilepsy who are unable to swallow perampanel tablets. Treatment should be initiated only by physicians who have appropriate experience in the treatment of epilepsy.
Perampanel suspension (Fycompa®) has been rejected for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy. The manufacturer failed to make a submission for this indication.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.